Source comparison
Best IGF-1 LR3 Dosage Recovery 2026: Dose-Response Comparison
20–40 mcg/day Moderate. Detectable proliferation markers, gradual strength/recovery gains Minimal glucose metabolism changes, low hypoglycemia risk Injury recovery models, older populations, conservative titration phases Best starting point for most research.
This comparison does not assign a generated winner or score.
- 20–40 mcg/day
- Moderate. Detectable proliferation markers, gradual strength/recovery gains
- Minimal glucose metabolism changes, low hypoglycemia risk
- Injury recovery models, older populations, conservative titration phases
- Best starting point for most research. Establishes individual response baseline with negligible adverse event risk
- 60–80 mcg/day
- High. Robust satellite cell recruitment, measurable hypertrophic signaling
- Moderate insulin sensitivity increase, possible transient joint discomfort
- Muscle hypertrophy studies, athletic performance research, post-surgical recovery
- Optimal balance between efficacy and safety for 6-week protocols in healthy populations
- 100–120 mcg/day
- Maximal. Peak mTOR activation, maximal protein synthesis upregulation
- Significant glucose uptake changes, increased GI discomfort and joint pain reports
- Advanced bodybuilding research, extreme recovery timelines, short-duration (≤4 week) studies
- Diminishing returns beyond 100 mcg. Receptor saturation and desensitisation risk outweigh marginal gains in most contexts